

Certificate of Analysis



Product Name/Description: RetroNectin® (Recombinant Human Fibronectin Fragment)

Cat. #: T100A

Lot #: AJ9G001

Storage Conditions: -20 degrees C

Expiration Date: September 2022

Package Size: 0.5 mg

Package Contents: 1. RetroNectin® (Recombinant Human Fibronectin Fragment) 1 µg/µl 0.5 ml

Product Documents: Documents for Takara Bio products are available for download at www.takara-bio.com

Source: E. coli expressing human fibronectin fragment CH-296

Quality Control Data:

Test items	Specifications	Results
Chromatographic purity	> 90.0%	99.0%
Biological activity tests		
(1) C-domain binding activity	> 80% of test control (TC)	Passed
(2) CS1 binding activity	> 80% of test control (TC)	Passed
(3) Heparin binding activity	conform to the standard	Passed

It is certified that this product meets above specifications.

Manager, Quality Assurance
TAKARA BIO INC.

Limited Use Label License & Patent Marking:

[M69] This product is covered by the claims of Japanese Patent No. 4406566 and its foreign counterpart patent claims.

Safety Information :

Please refer to our website for safety information :

<http://www.takara-bio.com>

Notice To Purchaser :

This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.

Also, do not use this product as food, cosmetic, or household item, etc.

Takara products may not be resold or transferred, modified for resale or transfer, or used to manufacture commercial products without written approval from TAKARA BIO INC.

If you require licenses for other use, please contact us by phone at +81 77 565 6973 or from our website.

<http://www.takara-bio.com>

Your use of this product is also subject to compliance with any applicable licensing requirements described on the product web page.

It is your responsibility to review, understand and adhere to any restrictions imposed by such statements.

All trademarks are the property of their respective owners. Certain trademarks may not be registered in all jurisdictions.